<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869476</url>
  </required_header>
  <id_info>
    <org_study_id>49RC18_0153_1</org_study_id>
    <nct_id>NCT03869476</nct_id>
  </id_info>
  <brief_title>Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.</brief_title>
  <acronym>BioScoreSMP</acronym>
  <official_title>Pilot Study for the Development of a Non-invasive Diagnostic Score to Differentiate Between Essential Thrombocythemia, Premyelofibrosis and Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study for the development of a non-invasive score for differentiating prefibrotic
      myelofibrosis from essential thrombocytosis and overt myelofibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the
      WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia
      (TE) and overt myelofibrosis (or primary myelofibrosis): prefibrotic myelofibrosis.
      Prefibrotic myelofibrosis patients seem to have a poorer prognosis compared to essential
      thrombocythemia in term of overall survival and myelofibrotic evolution. The dichotomy
      between these diseases is based on the bone marrow biopsy evaluation and is challenging with
      a lack of reproducibility showed in the literature.

      This study aims to develop a diagnostic non-invasive score for differentiating prefibrotic
      myelofibrosis from essential thrombocytosis and overt myelofibrosis.

      The parameters studied are :

        -  spleen fibrosis by elastography

        -  plasma cytokines levels

        -  mutationnal landscape by NGS

        -  CD34 circulating cells

      Bone marrow biopsy were reviewed by 2 anatomopathologists. Number of patients to be enrolled
      : 130
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WHO 2016 criteria for prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis</measure>
    <time_frame>At the time of diagnosis : disease classification</time_frame>
    <description>Assessment of the non-invasive diagnostic score against the WHO diagnosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Primary Myelofibrosis, Prefibrotic Stage</condition>
  <condition>Primary Myelofibrosis, Fibrotic Stage</condition>
  <arm_group>
    <arm_group_label>BioscoreSMP cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Non-invasive diagnosis score</intervention_name>
    <description>spleen fibrosis by elastography
plasma cytokines levels
mutationnal landscape by NGS
CD34 circulating cells</description>
    <arm_group_label>BioscoreSMP cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (18 years of age or older) with the diagnosis of essential thrombocytosis,
             prefibrotic myelofibrosis or overt myelofibrosis according to WHO 2016 criteria;

          -  Patient who has not received specific treatment for neoplasms;

          -  Patient who has signed the consent to participate in the study;

          -  Patient who has consented to be included in the &quot;Malignant Haemopathies&quot; collection at
             the University Hospital of Angers or Brest and for whom the samples necessary for the
             study are available in the biocollection.

        Exclusion Criteria:

          -  Patient with another hematologic neoplasm or progressive cancer at the time of
             diagnosis;

          -  Patient with a diagnosis of secondary myelofibrosis;

          -  Pregnant or breastfeeding woman;

          -  Person prived of liberty by judicial or administrative decision;

          -  Person subject to a legal protection measure;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Damien Luque Paz, Pharm.D.</last_name>
    <phone>0241355590</phone>
    <phone_ext>0033</phone_ext>
    <email>damien.luquepaz@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corentin Orvain, M.D.</last_name>
    <phone>0241356451</phone>
    <phone_ext>0033</phone_ext>
    <email>corentin.orvain@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Luque Paz</last_name>
      <phone>0241355353</phone>
      <phone_ext>0033</phone_ext>
      <email>damien.luquepaz@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Damien Luque Paz</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corentin Orvain</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - HÃ´pital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Christophe Ianotto</last_name>
      <phone>0298223786</phone>
      <phone_ext>0033</phone_ext>
      <email>jean-christophe.ianotto@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Ianotto</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Lippert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data of study protocol, Statiscal analysis plan and the infromed consent form will be made available after the study completion</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be available within 1 year of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed and requestors will be required to sign a data acess agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

